AARD

Aardvark Therapeutics
AARD

3.51 USD
-0.03
0.85%
At close Updated Mar 26, 4:00 PM EDT
Pre-market
After hours
3.56
+0.05
1.42%
1 day
-0.85%
5 days
-27.48%
1 month
-71.92%
3 months
-74.29%
6 months
-73.47%
Year to date
-73.39%
1 year
-62.74%
5 years
-75.47%
10 years
-75.47%
 

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 33

Healthcare Biotechnology
0
Funds holding %
of 8,095 funds
Explore Fund Trends
0
Analysts bullish %
of 5 analysts
See Analyst Outlook
0
Positive news %
of 15 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™